Trial · NCT04052425
Results by group90
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 90
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants Achieving a ≥ 75% Improvement From Baseline in the Face Vitiligo Area Scoring Index (F-VASI75) Score at Week 24 | Double-Blind Period: Ruxolitinib Cream 1.5% BID | 29.8 | percentage of participants | ||
| Percentage of Participants Achieving a ≥ 75% Improvement From Baseline in the Face Vitiligo Area Scoring Index (F-VASI75) Score at Week 24 | Double-Blind Period: Vehicle Cream BID | 7.4 | percentage of participants | ||
| Percentage of Participants Achieving a ≥ 50% Improvement From Baseline in the Face Vitiligo Area Scoring Index (F-VASI50) Score at Week 24 | Double-Blind Period: Ruxolitinib Cream 1.5% BID | 51.2 | percentage of participants | ||
| Percentage of Participants Achieving a ≥ 50% Improvement From Baseline in the Face Vitiligo Area Scoring Index (F-VASI50) Score at Week 24 | Double-Blind Period: Vehicle Cream BID | 16.9 | percentage of participants | ||
| Percentage of Participants Achieving a ≥ 90% Improvement From Baseline in the Face Vitiligo Area Scoring Index (F-VASI90) Score at Week 24 | Double-Blind Period: Ruxolitinib Cream 1.5% BID | 15.3 | percentage of participants | ||
| Percentage of Participants Achieving a ≥ 90% Improvement From Baseline in the Face Vitiligo Area Scoring Index (F-VASI90) Score at Week 24 | Double-Blind Period: Vehicle Cream BID | 2.2 | percentage of participants | ||
| Percentage of Participants Achieving a ≥ 50% Improvement From Baseline in the Total Body Vitiligo Area Scoring Index (T-VASI50) Score at Week 24 | Double-Blind Period: Ruxolitinib Cream 1.5% BID | 20.6 | percentage of participants | ||
| Percentage of Participants Achieving a ≥ 50% Improvement From Baseline in the Total Body Vitiligo Area Scoring Index (T-VASI50) Score at Week 24 | Double-Blind Period: Vehicle Cream BID | 5.1 | percentage of participants | ||
| Percentage of Participants Achieving a Vitiligo Noticeability Scale (VNS) of 4 or 5 at Week 24 | Double-Blind Period: Ruxolitinib Cream 1.5% BID | 24.5 | percentage of participants | ||
| Percentage of Participants Achieving a Vitiligo Noticeability Scale (VNS) of 4 or 5 at Week 24 | Double-Blind Period: Vehicle Cream BID | 3.3 | percentage of participants | ||
| Percentage Change From Baseline in Facial Body Surface Area (F-BSA) at Week 24 | Double-Blind Period: Ruxolitinib Cream 1.5% BID | -28.9 | Standard Error 2.22 | percentage change | |
| Percentage Change From Baseline in Facial Body Surface Area (F-BSA) at Week 24 | Double-Blind Period: Vehicle Cream BID | -9.5 | Standard Error 3.25 | percentage change | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) During the Double-Blind Period | Double-Blind Period: Ruxolitinib Cream 1.5% BID | 101 | Participants | ||
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) During the Double-Blind Period | Double-Blind Period: Vehicle Cream BID | 42 | Participants | ||
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) During the Treatment-Extension Period | Treatment-Extension Period: Ruxolitinib Cream 1.5% BID | 65 | Participants | ||
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) During the Treatment-Extension Period | Treatment-Extension Period: Vehicle Cream to Ruxolitinib Cream 1.5% BID | 31 | Participants | ||
| Percentage of Participants Achieving a ≥ 25% Improvement in the Face Vitiligo Area Scoring Index (F-VASI25) Score at Week 24 | Double-Blind Period: Ruxolitinib Cream 1.5% BID | 69.8 | percentage of participants | ||
| Percentage of Participants Achieving a ≥ 25% Improvement in the Face Vitiligo Area Scoring Index (F-VASI25) Score at Week 24 | Double-Blind Period: Vehicle Cream BID | 30.0 | percentage of participants | ||
| Percentage of Participants Achieving a ≥ %25, ≥ %50, ≥ 75%, and ≥ 90% Improvement in the Face Vitiligo Area Scoring Index (F-VASI25/50/75/90) Score at Week 52 | Treatment-Extension Period: Ruxolitinib Cream 1.5% BID | F-VASI25 | 89.6 | percentage of participants | |
| Percentage of Participants Achieving a ≥ %25, ≥ %50, ≥ 75%, and ≥ 90% Improvement in the Face Vitiligo Area Scoring Index (F-VASI25/50/75/90) Score at Week 52 | Treatment-Extension Period: Vehicle Cream to Ruxolitinib Cream 1.5% BID | F-VASI25 | 74.4 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04052425/results